An experimental ebola vaccine

An experimental ebola vaccine.
Early results suggest an empirical Ebola vaccine triggers an unaffected response and is safe to use. However, larger clinical trials in West Africa are needed to draw if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the UK This vaccine guts against the Zaire heave of Ebola currently circulating in West Africa penis enlargement pills in kennedy town. It doesn't contain communicable Ebola virus material, so it cannot cause Ebola infection in people who receive it.

The vaccine is being developed by the US National Institutes of Health and GlaxoSmithKline. The before doses of the vaccine for use in gargantuan clinical trials in West Africa have been delivered to Liberia. The Oxford University venture included 60 healthy volunteers who were monitored for 28 days after receiving three other doses of the vaccine. The volunteers will continue to be monitored for six months our site. "The vaccine was well tolerated.